News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Conference News HFSA 2024 Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity Todd Neale October 01, 2024
News Conference News ACC 2024 EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2 Shelley Wood April 07, 2024
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News EuroPCR 2022 Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot Michael O'Riordan May 23, 2022
News Conference News AHA 2020 Obesity Worsens Outcomes in COVID-19, Especially for Younger Adults Shelley Wood November 18, 2020
News Conference News ESC 2019 New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises Michael O'Riordan September 04, 2019
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018
News Conference News ESC 2018 ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients Todd Neale August 26, 2018
News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017
News Conference News ESC 2017 Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed Michael O'Riordan August 29, 2017
News Conference News AHA 2014 FACTOR-64: No Benefit to CTA Screening of Asymptomatic Patients with Diabetes November 16, 2014